Sarcopenia refers to age-related loss of muscle mass, strength and function. It leads to mobility issues and increased risk of falls in the elderly. Treatment of sarcopenia focuses on resistance and weight training exercises along with protein supplementation to help preserve or gain muscle mass. Some common supplements recommended for sarcopenia treatment include protein powders, creatine and HMB. Branched-chain amino acids from food sources like eggs, fish, meat and dairy are also beneficial.
Recent advancements have led to development of various prescription drugs aimed at targeting different pathways related to muscle loss. These drugs help in stimulating protein synthesis, reducing protein breakdown and muscle regeneration. Some of the approved drugs include teriparatide, enobosarm and anti-myostatin monoclonal antibodies. these drugs have shown encouraging results in clinical trials at helping build muscle mass and strength. Assistive devices like walkers and canes also help the elderly with limited mobility to maintain independence and prevent fall-related injuries.
The global Sarcopenia Treatment Market is estimated to be valued at US$ 3.47 Bn in 2024 and is expected to exhibit a CAGR of 9.5% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the major trends in the sarcopenia treatment market is rising popularity of nutraceuticals. Nutraceuticals provide all the benefits of nourishment along with medicinal properties. Research shows certain vitamins, minerals, proteins, fatty acids and botanical extracts have positive effects on muscle health and function. Many supplements introduced for sarcopenia contain optimized blends of ingredients like protein, vitamins D and K, resveratrol, quercetin, beta-alanine etc. Their easy availability as pills, powders or liquids and lack of adverse side-effects is driving consumers towards nutraceuticals over drugs. It is estimated nutraceuticals for sarcopenia treatment will be one of the fastest growing segments over the forecast period.
Threat of new entrants: The threat is moderate as R&D costs and regulatory approvals for new drugs are high barriers.
Bargaining power of buyers: The bargaining power of buyers is high as there are many treatment options available and price sensitivity is high.
Bargaining power of suppliers: The bargaining power of suppliers is moderate as suppliers have increased production capacities and capabilities.
Threat of new substitutes: The threat is high due to continuous innovation and new treatment approaches being researched and developed in areas like nutrition and exercise therapies.
Competitive rivalry: The competition is high among existing players to gain more market share.
The Global Sarcopenia Treatment Market Size is expected to witness high growth. The market is projected to reach US$ 5.29 Bn by 2031 from US$ 3.47 Bn in 2024, expanding at a CAGR of 9.5% during the forecast period.
Regional analysis: Europe is estimated to be the second largest market for sarcopenia treatment. The presence of major pharmaceutical companies and availability of advanced healthcare facilities are supporting the market growth in the region. Meanwhile, Asia Pacific exhibits the highest growth and is expected to witness a CAGR of over 11% during the forecast period. This can be attributed to rising geriatric population, growing healthcare spending, and increasing awareness about sarcopenia treatment in the region.
Key players: Key players operating in the sarcopenia treatment market are Yokogawa, General Electric, Rockwell Automation, MAVERICK Technologies, Emerson, Siemens, Rudolph Technologies, Honeywell International, ABB, Schneider Electric, Aspen Technology. Key players are focusing on new product launches and strategic collaborations with regional players to strengthen their market position.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it